Research into functional regenerative therapy combining HAL and regenerative medicine
First written in FY2017-Q1. 4 of 6 entries say "Restated". Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026RestatedAnnual report
「Building A of the Cybernics Medical Innovation Base is operating in the Tonomachi International Strategic Zone in Kawasaki, promoting the systematization of cybernics therapies combining HAL with regenerative medicine and pharmaceuticals, as well as the development of technologies integrating medical and biotechnology with AI, robotics, and information technology. The company is advancing the move-in of life sciences companies, with business synergies anticipated, and collaboration with C-Startup partners in regenerative medicine and drug discovery.」
The company has reaffirmed its policy of advancing at the Tonomachi Building A research into combination treatments involving HAL, regenerative medicine and pharmaceuticals, as well as integrated research spanning medicine and biotechnology, AI, robotics and information technology. - FY2018AdvancedAnnual report
「The Group will continue to promote research and development and product development for cybernic systems, including cybernic devices and cybernic interfaces, using cutting-edge cybernetics technologies in collaboration with universities, research institutions, hospitals, government agencies and companies in Japan and overseas, as well as research and development into combination therapies involving pharmaceuticals and regenerative medicine.」
The scope of the stated R&D policy has been expanded to include combination therapies involving pharmaceuticals, in addition to combinations of HAL and regenerative medicine. - FY2017RestatedAnnual report
「We are also advancing research into innovative functional regenerative therapy combining medical HAL® and regenerative medicine, working with leading medical research institutions to make it available to as many paralyzed patients as possible.」
Research into functional regenerative therapy combining HAL and regenerative medicine continues. - FY2017-Q3RestatedAnnual report
「We are also advancing research into innovative functional regenerative therapy combining medical HAL® and regenerative medicine, working with leading medical research institutions to make it available to as many paralyzed patients as possible.」
Research into functional regenerative therapy combining HAL and regenerative medicine continues in collaboration with medical research institutions. - FY2017-Q2RestatedAnnual report
「We are also advancing research into innovative functional regenerative therapy combining medical HAL® and regenerative medicine, working with leading medical research institutions to make it available to as many paralyzed patients as possible.」
Research into functional regenerative therapy combining HAL and regenerative medicine continues in collaboration with leading medical research institutions. - FY2017-Q1First statedAnnual report
「We are also advancing research into innovative functional regenerative therapy combining HAL® and regenerative medicine, working with leading medical research institutions to expand its applicability to as many paralyzed patients as possible.」
The company has disclosed for the first time its initiative to advance, in collaboration with leading medical research institutions, research into functional regenerative therapy combining HAL and regenerative medicine to expand its applicability to paralyzed patients.